Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

The test substance has no potential for bioaccumulation as determined via valid two rat studies (Riess 1977 and Knight 2007) using 14C-radiolabelled material.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential

Additional information

Both available studies (Riess, W. (1977) and Knight LJL (2007)) show that the substance is absorbed after ingestion and that it is distributed to liver and kidney. Elimination was only investigated in the first study, where a single radioactive dose of 10 mg/kg bw was used. Elimination occurred mostly via the urine within 48h. About 25% of the radioactive dose was recovered in the feces.

Metabolites were not examined, but it is expected that the phenolic hydroxy group will be conjugated with glucuronic acid or sulfonic acid in both liver and extrahepatic tissues. Oxidative metabolism at the methyl group is also possible. A specific investigation on effects on liver (Schmid 1980 and Lake (undated)) showed that the substance induces UDP-glucuronosyltransferases, but no microsomal oxidases in rat liver of both sexes. It is expected that the substance will be taken up after skin contact or inhalation and that the route of exposure does not influence systemic toxicity.

No experimental data on toxicokinetic properties is available for inhalation and skin contact. For both routes of exposure, uptake is expected. The substance causes skin sensitization and QSAR tool DEREK identifies the ortho-position of the cresol as the structural alert for protein binding (Ciba 2009) Metabolism and elimination is expected to be identical to oral exposure.